Range of Drugs Eligible for Premium for New Drug Development May Be Reviewed; Industry Needs to Dispel Suspicions

The full-scale implementation and perpetuation of the premium for new drug development and elimination of off-label drug use may be facing a new hurdle. Shuji Shirakawa, executive managing director of the National Federation of Health Insurance Societies (Kenporen) and a...read more